Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The page’s footer/site revision version is updated from v3.5.2 to v3.5.3.
    Difference
    0.1%
    Check dated 2026-04-25T18:43:58.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-18T13:36:42.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    50 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 on the page.
    Difference
    0.1%
    Check dated 2026-03-21T01:13:13.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Updated site revision from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-06T16:22:49.000Z thumbnail image
  7. Check
    86 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.4.2, replacing v3.4.1, which is a minor update with no changes to study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T15:55:01.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    The recruitment/status changed to Completed. The study completion date (Actual) is listed as 2026-01-09, with updates through 2026-01-30 and a new revision (v3.4.1).
    Difference
    0.4%
    Check dated 2026-02-05T11:27:11.000Z thumbnail image

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.